Dacetuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dacetuzumab
Accession Number
DB12589  (DB05539)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
SGN-40
Categories
UNII
UT59FF4T5X
CAS number
880486-59-9

Pharmacology

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 5Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dacetuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Dacetuzumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Dacetuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Dacetuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Dacetuzumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Dacetuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacetuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Dacetuzumab.
AmatuximabThe risk or severity of adverse effects can be increased when Dacetuzumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Dacetuzumab.
Food Interactions
Not Available

References

General References
  1. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15;64(8):2846-52. [PubMed:15087402]
External Links
PubChem Substance
347911348
Wikipedia
Dacetuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMultiple Myeloma (MM)3
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
Gene Name
CD40
Uniprot ID
P25942
Uniprot Name
Tumor necrosis factor receptor superfamily member 5
Molecular Weight
30618.76 Da
References
  1. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15;64(8):2846-52. [PubMed:15087402]

Drug created on October 20, 2016 17:03 / Updated on November 02, 2018 07:27